12:00 AM
 | 
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eribulin mesylate regulatory update

FDA accepted for filing and granted Priority Review to an NDA from Eisai for eribulin mesylate to treat locally advanced or metastatic...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >